True North Therapeutics is a biotechnology company developing a pipeline of novel therapies that selectively target the Complement pathway of the immune system to address fundamental mechanisms in diseases with high unmet need, including rare diseases. The company's lead drug candidate, TNT009, offers a novel approach for treating Complement-mediated diseases by selectively inhibiting a target in the Classical Complement pathway. True North's antibody drug development is focused on the treatment of rare diseases mediated by the Complement system in the hematologic, kidney transplant, and skin therapeutic areas.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/07/15 | $35,000,000 | Series B |
Baxter Ventures MPM Capital OrbiMed Advisors SR One | undisclosed |
| 12/03/15 | $40,000,000 | Series C |
Baxalta Ventures Cowen Private Investments MPM Capital New Leaf Venture Partners OrbiMed Advisors Perceptive Advisors SR One | undisclosed |
| 10/18/16 | $45,000,000 | Series D |
Franklin Templeton HBM Healthcare Investments Perceptive Advisors Redmile Group | undisclosed |
